CADDRA would like to add its support to a new position paper on newer medications published by the Canadian Psychiatric Association. Download the PDF of “Access to Newer Medications” here. The paper points out that expensive long-acting newer medications for ADHD may be cost effective in the long term. “These medications result in improved school and work performance by improving adherence and reducing abuse potential.” Currently most of these medications are not covered by all Canadian public plans because of their cost.